The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

A groundbreaking trial in the U.K. has released data on eight babies born through a special IVF procedure to lower their risk of mitochondrial DNA disease.

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...